|
OSI Pharma., Inc. v. Mylan Pharma. Inc., 09-0185 (D. Del.)
|
Tarceva® (erlotinib hydrochloride tablets)
|
RE41,065
6,900,221
7,087,613
|
N/A
|
|
Orion Corp. v. Mylan Pharma. Inc., 12-0523 (D. Del.)
|
Stalevo® (carbidopa / levodopa / entacapone)
|
5,466,194
6,500,867
6,797,732
|
Mylan to launch authorized generic product immediately upon approval of settlement agreement.
Mylan will also launch its generic ANDA product, subject to FDA approval.
|
|
Warner Chilcott Co., LLC v. Mylan Inc., 11-3262 (D.N.J.)
|
Loestrin® (norethindrone acetate / ethinyl estradiol)
|
5,552,394
|
Defendants stipulate to infringement.
|
|
Roche Palo Alto LLC v. Lupin Pharma. Inc., 10-3561 (D.N.J.)
|
Ranexa® (ranolazine)
|
6,303,607
6,479,496
6,503,911
6,525,057
6,562,826
6,617,328
6,620,814
6,852,724
6,864,258
|
N/A
|
|
Warner Chilcott Labs. Ireland Ltd. v. Impax Labs. Inc., 08-6304 (D.N.J.)
|
Doryx® (doxycycline hyclate)
|
6,958,161
|
Warner Chilcott PLC and Mayne Pharma International Pty. Ltd. will pay $12 million to Mylan Inc. and Mylan Pharma. Inc. in full satisfaction of Mylan’s claim under the bond.
Mylan’s damages claim will be dismissed and the bond will be released.
|
|
Avanir Pharma. Inc. v. Wockhardt Ltd., 11-0758 (D. Del.)
|
Nuedexta® (dextromethorphan hydrobromide / quinidine sulfate)
|
7,659,282
RE38,115
|
Avanir has signed a licensing agreement with Wockhardt allowing it to launch an authorized generic on July 30, 2026, two weeks before the last patent covering Nuedexta is set to expire.
|
|
Merck Sharp & Dohme Corp. v. Sandoz Inc., 12-6077 (D.N.J.)
|
Zetia® (ezetimibe)
|
RE42,461
5,846,966
7,030,106
7,612,058
|
Sandoz is enjoined until April 25, 2017 from making, using, or selling its generic product. The patents-in-suit expire between 2014 and 2022.
|
|
Purdue Pharma LP v. Par Pharma. Cos. Inc., 11-2038 (S.D.N.Y.)
|
OxyContin® (oxycodone hydrochloride)
|
6,488,963
7,674,799
7,674,800
7,683,072
7,776,314
|
Purdue’s infringement suit was dismissed with prejudice in exchange for Par waiving any possible antitrust or other claim against Purdue arising from conduct or events prior to the date of settlement.
|